in this video, Deric Park, MD, discusses a phase 1/2 study of IGV-001, a novel treatment for #glioblastoma .

targetedonc.com/view/about-the…

The #FDA has approved one of the first human papillomavirus (HPV) self-collection solutions for use in the US. #GYNCSM

targetedonc.com/view/fda-green…

Versamune HPV + pembrolizumab led to a promising best overall response in a cohort of 53 patients with HPV 16-positive recurrent or metastatic head and neck squamous cell carcinoma. #HNSCC

targetedonc.com/view/versamune…

A recent survey revealed 30% of healthcare leaders view health equity solely as a social issue. But here's the data-driven truth for healthcare professionals...targetedonc.com/view/how-data-…

Uncover the Inside Scoop on #FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma With Christopher Flowers, MD! Don't miss this exclusive interview MD Anderson Cancer Center.

targetedonc.com/view/behind-th…

Because of federal budgetary constraints and priorities in Washington, DC, we are entering a time of major risk and negative impact on the NCI via the flat NIH budget, which may result in cuts to cancer research funding across the board. UPMC Hillman Cancer Center

targetedonc.com/view/questions…

ICYMI: The FDA's ODAC voted 12 to 2 in favor of imetelstat as a promising treatment for #MDS and anemia patients who rely on transfusions and have no success with other treatments.

targetedonc.com/view/fda-odac-…

WATCH: Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in #SCLC . #LCSM | @ahntoday

targetedonc.com/view/discussin…

The FDA has cleared an investigational new drug application for SynKIR-310. With this, a phase 1 clinical trial evaluating SynKIR-310 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphomas may proceed. #LYMSM

targetedonc.com/view/fda-clear…

Abdullah Khan, MBBS, discussed the different outcomes with ide-cel in patients with R/R multiple #myeloma in both the clinic and real-world settings.

targetedonc.com/view/how-bcma-…

177Lu-PSMA-617 transforms treatment for metastatic prostate cancer, urging more oncology programs to adopt it sooner for better patient outcomes. #PCSM | Olsi Gjyshi

targetedonc.com/view/expanding…

Adjuvant pembrolizumab showed a significant and clinically meaningful improvement in OS when compared with placebo in patients with #ccRCC , according to findings from KEYNOTE-564. #KCSM | Toni Choueiri, MD Dana-Farber Tom Powles

targetedonc.com/view/adjuvant-…

A fast track designation has been granted SNB-101 by the #FDA for #SCLC .

targetedonc.com/view/fda-grant…

The vibostolimab + pembrolizumab coformulation arm of the phase 3 KeyVibe-010 study investigating the agents as an adjuvant treatment in resected high-risk #melanoma will be discontinued due to futility, according to Merck.

targetedonc.com/view/pembroliz…

WATCH: Deric Park, MD, discusses what challenges remain in treating #glioblastoma , as well as new avenues for research in this difficult disease. JTCancerCenter

targetedonc.com/view/obstacles…

During an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz MD of Weill Cornell Medicine highlighted the hurdles in treating brain tumors, discussed emerging therapies, & strategies for overcoming the blood-brain barrier. NewYork-Presbyterian

targetedonc.com/view/brain-can…

Our Weill Cornell Medicine NewYork-Presbyterian Dermatology colleague Dr. Niroshana Anandasabapathy (@niroanandalab) explains how advancements in detection and treatment are improving #Melanoma outcomes: bit.ly/4b7laEV #Melanoma Monday (cc: Targeted Oncology)

The experimental regimen of the phase 3 CheckMate -73L study investigating nivolumab and ipilimumab or the treatment of unresectable stage III #NSCLC did not improve progression-free survival, missing the primary end point of the study. #LCSM

targetedonc.com/view/phase-3-c…

WATCH: Experts Discuss Adjuvant Immunotherapy in Renal Cell Carcinoma #KCSM #RCC | Sumanta K. Pal, MD, FASCO City of Hope | Orange County @cityofhope UC San Diego Health Rana McKay Thomas Hutson, DO, PharmD, PhD FACP

targetedonc.com/view/adjuvant-…